Insider Selling: Phreesia (NYSE:PHR) General Counsel Sells 1,241 Shares of Stock

Key Points

• Phreesia's General Counsel, Allison Hoffman, sold 1,241 shares at an average price of $22.36, reducing her position by 0.91% to a total of 135,737 shares valued at approximately $3 million.
• The company's stock is currently trading at $23.11 and has a market capitalization of $1.38 billion, with a P/E ratio of -55.02.
• Analysts have a consensus rating of Moderate Buy for Phreesia stock, with a price target averaging $33.85, following several upgrades from investment firms.

Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 1,241 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $27,748.76. Following the completion of the sale, the general counsel directly owned 135,737 shares of the company's stock, valued at approximately $3,035,079.32. The trade was a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Phreesia Stock Up 0.7%

Shares of NYSE PHR traded up $0.17 during trading hours on Tuesday, hitting $23.11. The company had a trading volume of 370,773 shares, compared to its average volume of 611,887. The stock has a market capitalization of $1.38 billion, a P/E ratio of -55.02 and a beta of 0.68. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $32.76. The firm's 50 day moving average is $26.02 and its 200-day moving average is $25.99.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.08. The company had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The firm's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

A number of hedge funds have recently made changes to their positions in PHR. GAMMA Investing LLC boosted its stake in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after purchasing an additional 5,621 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Phreesia during the first quarter valued at about $462,000. QRG Capital Management Inc. boosted its stake in shares of Phreesia by 8.0% during the first quarter. QRG Capital Management Inc. now owns 11,118 shares of the company's stock valued at $284,000 after purchasing an additional 827 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Phreesia during the first quarter valued at about $205,000. Finally, Bessemer Group Inc. boosted its stake in shares of Phreesia by 23.2% during the first quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after purchasing an additional 8,978 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PHR has been the topic of a number of research analyst reports. Needham & Company LLC increased their price target on Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Citigroup restated an "outperform" rating on shares of Phreesia in a research report on Monday, September 8th. DA Davidson upgraded Phreesia to a "strong-buy" rating in a research report on Monday, September 8th. Truist Financial raised their price target on Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Finally, Canaccord Genuity Group lifted their target price on Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Phreesia currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.85.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.